Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man.

1. Epoprostenol (prostacyclin, PGI2) has been evaluated in clinical trials in peripheral vascular disease and other conditions chiefly on the basis of its platelet inhibitory properties. These therapeutic evaluations have proceeded in the absence of evidence as to the optimum infusion regimen for ep...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sinzinger, H, Fitscha, P, Kaliman, J, Silberbauer, K, O'Grady, J
Médium: Artigo
Jazyk:Inglês
Vydáno: 1987
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1386332/
https://ncbi.nlm.nih.gov/pubmed/3325091
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky